article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. The requirements When handling personalised medicines, time is of the essence.

article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. The rights to the oRNA-LNP technology platform of Orna will be retained by the company, which will also progress various other fully owned programmes in oncology and genetic disease areas.

RNA 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

n-Lorem Foundation Preps First Doses to Treat Ultra-Rare Disease Patients for Free

The Pharma Data

n-Lorem Foundation has taken on a challenge that many nations consider too great: treating patients with ultra-rare diseases (which affect 30 or fewer people) for free, for life. Genetic diseases are vastly more common and more complex than we used to think.”. Patient dosing is expected to begin later this year. “No

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

The assumption is SciNeuro will start with Parkinson’s disease and pain in addition to rare genetic diseases, after scaling up staffing. . A supporting pipeline has medicines to target these key pathways to reverse or eradicate disease and extend the years of healthy life remaining.

RNA 52
article thumbnail

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

The Pharma Data

While disease progression is slower in patients with later-onset SMA, there are significant unmet needs. “We SMA is a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, resulting in the irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement.

article thumbnail

Transcending expectations for cell & gene therapy development

Drug Discovery World

Clinical trial sponsors need to coordinate the delivery of investigational medicinal products to clinical sites and the collection of samples from participants after they receive treatment. There are over 7,000 genetic diseases that could potentially be cured using gene therapy 10. Conclusion. Molecular therapy. link] omtm.2021.04.001.